ArticleTranslational psychiatry2026
Gamma and beta power and the 1/f slope vary across a spectrum of depression severity.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Depression is a highly prevalent mental disorder that impacts an individual's functioning, societal productivity, and quality of life. It is associated with disrupted neural activity (e.g., balance of excitation-inhibition) across networks implicated in emotional processing, such as between prefrontal and limbic regions. Gamma and beta activity measured with electroencephalography (EEG) differ between healthy individuals and those with depression, and predict treatment outcomes following pharmacological intervention. However, to date research has focussed on binary comparisons between individuals with a clinical depression diagnosis relative to healthy control populations, providing limited insight into how these measures may shift as a function of illness severity. To establish the utility of EEG measures as potential biomarkers for depression, an improved understanding across the spectrum of symptom profiles is required. Here, we aimed to bridge this gap and investigate changes in beta and gamma power and the 1/f slope in resting-state EEG across a spectrum of mild to severe depression symptom presentations. In line with expectations, we demonstrate graded alterations to gamma and beta power and the 1/f slope across a spectrum of depression severity. Our findings provide critical new insights into the neurophysiological signature of depression symptoms, and highlight the utility of EEG markers to inform future precision psychiatry approaches to more effectively assess and treat depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.